Literature DB >> 8502478

The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.

R L Zastawny1, R Salvino, J Chen, S Benchimol, V Ling.   

Abstract

The overexpression of P-glycoprotein is thought to be responsible for resistance to chemotherapy in some non-responsive cancers. The mechanism by which P-glycoprotein is overexpressed in human tumors is poorly understood. However, several lines of evidence suggest that the major regulatory mechanism of P-glycoprotein overexpression in human tumors is at the transcriptional level. During tumor progression one of the most commonly observed alterations is mutation of the p53 tumor-suppressor gene. It has been shown that the p53 protein plays a role in transcriptional regulation. To gain insight into the effect p53 protein may have on P-glycoprotein promoter activity, we transiently co-transfected plasmids containing the hamster pgp1 or human mdr1 promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene with plasmids encoding either wild-type or mutant p53 protein into Chinese hamster ovary (CHO) cells. In this report, we show that wild-type p53 protein represses P-glycoprotein promoter activity, while mutant forms of p53 protein enhance P-glycoprotein promoter activity. Furthermore, we present data which indicate that the transcriptional regulatory effects of p53 are mediated through interactions with pgp1/mdr1 core promoter sequences. These findings have implications for our understanding of the molecular mechanism(s) by which p53 protein functions as a transcriptional regulator of gene expression. In addition, our results suggest a mechanism by which P-glycoprotein may be overexpressed in human cancers that also express mutant forms of p53 protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8502478

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Modulation of MDR/MRP by wild-type and mutant p53.

Authors:  O Bähr; W Wick; M Weller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Higher Level of P-glycoprotein Expression in Human Breast Cancer Cells after Radiation Therapy.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

3.  p-Glycoprotein expression as a predictor of breast cancer recurrence.

Authors:  S Gregorcyk; Y Kang; D Brandt; P Kolm; G Singer; R R Perry
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases.

Authors:  E de Kant; I Heide; C Thiede; R Herrmann; C F Rochlitz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

Authors:  J H Ludes-Meyers; M A Subler; C V Shivakumar; R M Munoz; P Jiang; J E Bigger; D R Brown; S P Deb; S Deb
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

6.  Methylation of RASSF1A gene promoter is regulated by p53 and DAXX.

Authors:  Hailong Zhang; Jing He; Jiansha Li; Dan Tian; Lubing Gu; Muxiang Zhou
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

7.  Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.

Authors:  Long Gu; Jasmine Chen; Timothy W Synold; Barry M Forman; Susan E Kane
Journal:  J Pharmacol Exp Ther       Date:  2013-03-26       Impact factor: 4.030

8.  A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging.

Authors:  Long Gu; Walter M Tsark; Donna A Brown; Suzette Blanchard; Timothy W Synold; Susan E Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

9.  Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter.

Authors:  C V Shivakumar; D R Brown; S Deb; S P Deb
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

10.  Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.

Authors:  J Chen; J Lin; A J Levine
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.